You are here:

methylnaltrexone bromide (Relistor)


Following a full submission

methylnaltrexone (Relistor®) is accepted for restricted use within NHS Scotland for treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. It is restricted to use by physicians with expertise in palliative care.

Methylnaltrexone has been shown to be superior to placebo in achieving bowel movement in terminally ill patients with opioid-induced constipation already receiving a stable laxative regimen.

Drug Details

Drug Name: methylnaltrexone bromide (Relistor)
SMC Drug ID: 518/08
Manufacturer: John Wyeth and Brother Limited
Indication: Opioid-induced constipation in advanced illness patients
BNF Category:
Sub Category: 1.6 Laxatives
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 December 2008